Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale

Sentinel lymph nodes (SLN) are more likely to contain metastatic breast carcinoma than non-SLNs. The limited number of SLNs compared with an axillary dissection has prompted more comprehensive lymph node analysis increasing detection of micrometastases. National data show that many women previously classified node negative are now classified minimally node positive. As a result, our nodal classification and cancer staging have evolved to recognize the continuum of nodal tumor burden rather than a simplistic dichotomous stratification. It is quite clear that the more sections we evaluate from SLNs the more metastases we identify; however, it is impractical to expect the practicing pathologist to mount, stain, and microscopically examine every section through the SLN paraffin blocks. Despite recommendations from the College of American Pathologists and the American Society of Clinical Oncology, heterogeneity in the approach to SLN evaluation exists. What is needed is adherence to a standardized evaluation protocol. The most important aspect of the sentinel node examination is careful attention to slicing the SLN no thicker than 2.0 mm and correct embedding of the slices to assure we identify all macrometastases larger than 2.0 mm. A single section from blocks prepared in this manner will identify all macrometastases present but smaller metastases will be missed. The prognostic significance of these missed micrometastases is still being evaluated as we await SLN outcome studies. In the context of the new molecular classification of breast cancer, subgroups may be identified where detection of micrometastases has clinical significance. It is critical that both clinicians and pathologists understand there is a random component to micrometastasis distribution within the three-dimensional paraffin tissue blocks. If we ultimately adopt more comprehensive microscopic evaluation of SLNs, the candidate sampling strategies need to be carefully considered in the context of statistically valid sampling strategies.

[1]  G. Murphy,et al.  Management and survival of female breast cancer: Results of a national survey by the American college of surgeons , 1980, Cancer.

[2]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[3]  T. Julian,et al.  Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer , 2006, Cancer.

[4]  R. Hutter,et al.  Significance of Axillary Macrometastases and Micrometastases in Mammary Cancer , 1971, Annals of surgery.

[5]  A. Giuliano,et al.  The Prognostic Significance of Micrometastases in Breast Cancer: A SEER Population-Based Analysis , 2007, Annals of Surgical Oncology.

[6]  Donald L. Weaver,et al.  NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial , 2004, Annals of Surgical Oncology.

[7]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[8]  Barbara L. Smith,et al.  The effect of tumor size and lymph node status on breast carcinoma lethality , 2003, Cancer.

[9]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[10]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[11]  D. Weaver,et al.  Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma , 2000, Cancer.

[12]  D. Weaver,et al.  Metastasis Detection in Sentinel Lymph Nodes: Comparison of a Limited Widely Spaced (NSABP Protocol B-32) and a Comprehensive Narrowly Spaced Paraffin Block Sectioning Strategy , 2009, The American journal of surgical pathology.

[13]  D. Weaver,et al.  Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. , 1993, Surgical oncology.

[14]  P. V. van Diest,et al.  Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. , 2008, European journal of cancer.

[15]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[16]  A. Giuliano,et al.  Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Peterse,et al.  Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology , 2004, Journal of Clinical Pathology.